LUND, Sweden, June 30, 2020 /PRNewswire/ -- Immunovia AB (publ)
("Immunovia") today announced that the number of shares and votes
in Immunovia has changed due to the fact that shares have been
registered after the directed share issue which was carried out in
June 2020.
Through the registration of shares after the new issue, the
number of outstanding shares and votes increases by 2,948,228 from
19,654,853 to 22,603,081. The share capital increases by
SEK 147,411.40 from SEK 982,742.65 to SEK
1,130 154.05.
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 09:00 CET on
June 30, 2020.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q4
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Julie Silber
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/change-in-the-number-of-shares-and-votes-in-immunovia-ab--publ-,c3144609
The following files are available for download:
https://mb.cision.com/Main/13121/3144609/1271633.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/change-in-the-number-of-shares-and-votes-in-immunovia-ab-publ-301085636.html
SOURCE Immunovia AB